Bibliothèque

Evaluation of Combined Lipiodol and Epirubicin-Loaded Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.

PURPOSE: To evaluate the short-term clinical efficacy, side effects and risk factors affecting the clinical effectiveness of the combination of lipidol and epirubicin-loaded drug-eluting bead transart…

Thérapies de Conversion

Song, D., Feng, X., Zhou, Y., Cai, Y., & Xue, T. (2025). Evaluation of Combined Lipiodol and Epirubicin-Loaded Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.. J Hepatocell Carcinoma, 12, 2723-2733. https://doi.org/10.2147/JHC.S565056

01/01/2025 Lire →

Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy.

BACKGROUND: Conversion therapy provides patients with intermediate-advanced hepatocellular carcinoma (HCC) an opportunity for radical resection, but the prognostic significance of residual tumor in re…

Thérapies de Conversion

Zhang, H., Yang, T., Huang, L., Li, B., Xu, H., & Wei, Y. (2025). Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy.. Front Immunol, 16, 1704239. https://doi.org/10.3389/fimmu.2025.1704239

01/01/2025 Lire →

Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis.

BACKGROUND: Due to its rarity, synchronous double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma (sdpHCC-ICC) presents significant challenges for preoperative diagnosis and is la…

Thérapies de Conversion

He, Y. C., Dai, X. Y., Lv, Y. H., Yang, X. J., Xie, Q. Y., Xie, S. N., Cai, Y. S., Gao, F. W., & Lan, T. (2025). Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis.. Front Oncol, 15, 1670818. https://doi.org/10.3389/fonc.2025.1670818

01/01/2025 Lire →

Immunotherapy in conversion therapy for gastric cancer: current status, progress, and challenges.

Gastric cancer remains a global health burden due to its late diagnosis and poor prognosis. Conversion therapy aims to make the initially unresectable tumor resectable through systemic treatment, prov…

Thérapies de Conversion

Su, Y., Zhang, X., & Deng, W. (2025). Immunotherapy in conversion therapy for gastric cancer: current status, progress, and challenges.. Front Oncol, 15, 1637657. https://doi.org/10.3389/fonc.2025.1637657

01/01/2025 Lire →

Screening Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Patients After Tyrosine Kinase Inhibitor Plus PD-1/PD-L1 Antibody Therapy: A Multicenter Retrospective Study.

BACKGROUND: Conversion therapies after immune checkpoint inhibitors (ICIs) plus tyrosine-kinase inhibitors (TKIs) provide curative surgery chance and prolong survival for unresectable hepatocellular c…

Thérapies de Conversion

Jin, Z., Li, X., Lv, L., Zhang, B., Ma, X., Chen, S., You, J., Wu, X., Wang, L., Liu, X., Wang, F., Chen, X., Yu, L., Zhang, S., & Zhang, L. (2025). Screening Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Patients After Tyrosine Kinase Inhibitor Plus PD-1/PD-L1 Antibody Therapy: A Multicenter Retrospective Study.. J Hepatocell Carcinoma, 12, 1921-1941. https://doi.org/10.2147/JHC.S523476

01/01/2025 Lire →

A stage IV lung squamous cell cancer patient with brain metastases, high PD-L1 & TMB, achieves pCR and long-term survival after immune-chemotherapy and radical surgery: a case report and literature review.

Brain metastases occur in 40% of advanced NSCLC patients, with poorer prognosis in squamous subtypes. Immune checkpoint inhibitors (ICIs) combined with chemotherapy have revolutionized treatment, yet …

Thérapies de Conversion

Xu, X., & Ma, Z. (2025). A stage IV lung squamous cell cancer patient with brain metastases, high PD-L1 & TMB, achieves pCR and long-term survival after immune-chemotherapy and radical surgery: a case report and literature review.. Front Immunol, 16, 1601125. https://doi.org/10.3389/fimmu.2025.1601125

01/01/2025 Lire →

Comparison of survival benefit and safety profile between lenvatinib and donafenib as conversion therapy in patients with hepatocellular carcinoma.

OBJECTIVE: To compare the survival benefit and safety profiles between lenvatinib and donafenib when used as conversion therapies for patients with hepatocellular carcinoma (HCC) at the China National…

Thérapies de Conversion

Hou, Y., Gao, Z., Han, Y., Liu, C., Su, X., & Zhang, D. (2025). Comparison of survival benefit and safety profile between lenvatinib and donafenib as conversion therapy in patients with hepatocellular carcinoma.. Am J Transl Res, 17(5), 3496-3504. https://doi.org/10.62347/PBLA2928

01/01/2025 Lire →

Rare Gingival Metastasis Occurring After Conversion Therapy Followed by Resection of Initially Unresectable Hepatocellular Carcinoma: A Case Report.

Gingival metastases from hepatocellular carcinoma (HCC) are exceedingly rare and highly prone to be misdiagnosed without biopsy. Here, we report an initially unresectable HCC patient who received effe…

Thérapies de Conversion

Zhan, J., Huang, H., Zhan, T., Liu, X., & Cheng, Q. (2025). Rare Gingival Metastasis Occurring After Conversion Therapy Followed by Resection of Initially Unresectable Hepatocellular Carcinoma: A Case Report.. J Hepatocell Carcinoma, 12, 705-713. https://doi.org/10.2147/JHC.S514983

01/01/2025 Lire →

Development of a Nomogram for Prognostic Prediction of Large Hepatocellular Carcinoma With HBV After TACE Combined Conversion Therapy.

BACKGROUND: Surgical resection (SR) following transarterial chemoembolization (TACE) is a promising option for large hepatocellular carcinoma (LHCC) with HBV, and identification of these patients at h…

Thérapies de Conversion

Xu, W., Ding, X., Xu, Y., Zhang, Y., Xu, H., Guo, L., & Li, L. (2025). Development of a Nomogram for Prognostic Prediction of Large Hepatocellular Carcinoma With HBV After TACE Combined Conversion Therapy.. Hepat Med, 17, 1-12. https://doi.org/10.2147/HMER.S481334

01/01/2025 Lire →

Systemic Treatment for Unresectable Hepatocellular Carcinoma: A Surgeon's Perspective.

In recent years, the standard treatment for hepatocellular carcinoma (HCC) has changed dramatically due to the emergence of potent systemic treatment options. These advanced therapies have led to incr…

Thérapies de Conversion

Zhu, X. D., Zhao, L., Li, B., Cheng, Y., & Sun, H. C. (2025). Systemic Treatment for Unresectable Hepatocellular Carcinoma: A Surgeon's Perspective.. J Hepatocell Carcinoma, 12, 399-413. https://doi.org/10.2147/JHC.S504457

01/01/2025 Lire →

Surgical resection versus thermal ablation: comparison of sequential options after successful TACE downstaging therapy for unresectable hepatocellular carcinoma.

BACKGROUND: Transarterial chemoembolization (TACE) is an effective and safe downstaging therapy for hepatocellular carcinoma (HCC). However, the selection of sequential therapeutic modalities is still…

Thérapies de Conversion

An, C., Wu, S., Zuo, M., Li, W., Li, K., & Wu, P. (2025). Surgical resection versus thermal ablation: comparison of sequential options after successful TACE downstaging therapy for unresectable hepatocellular carcinoma.. Ther Adv Med Oncol, 17, 17588359241306648. https://doi.org/10.1177/17588359241306648

01/01/2025 Lire →

ASO Author Reflections: Can Conversion Therapy be an Option for Advanced Esophageal Cancer with Distant Metastases?

Thérapies de Conversion

Tsuji, T., Matsuda, S., Sato, Y., Tanaka, K., Sasaki, K., Watanabe, M., Hamai, Y., Nasu, M., Saze, Z., Nakashima, Y., Nomura, M., Yamamoto, S., Booka, E., Ishiyama, K., Bamba, T., Sakanaka, K., Tsushima, T., Takeuchi, H., Kato, K., & Kawakubo, H. (2025). ASO Author Reflections: Can Conversion Therapy be an Option for Advanced Esophageal Cancer with Distant Metastases?. Ann Surg Oncol, 32(1), 325-326. https://doi.org/10.1245/s10434-024-16310-9

01/01/2025 Lire →